Related Experiment Video
Updated: Jan 14, 2026
Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
Published on: December 3, 2019
Comparison of Clinical Characteristics of Pneumocystis Pneumonia with or without Human Immunodeficiency Virus: A
Juyeong Lee1, Joong Sik Eom1, Hye Jin Shi1
1Division of Infectious Diseases, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Purpose:
Pneumocystis jirovecii pneumonia (PJP) is a life-threatening infection. The prevalence of PJP in patients without human immunodeficiency virus (HIV) (non-HIV-PJP) is increasing. Previous studies have separately evaluated the clinical characteristics of PJP patients with and without HIV infection. Therefore, this study aimed to comparatively analyze the clinical characteristics of PJP patients with and without HIV.
Materials And Methods:
We retrospectively reviewed patients with PJP who were admitted to a single tertiary center for 15 years. PJP patients were classified according to the presence or absence of HIV, and differences in their clinical characteristics and prognoses were analyzed. Forty-four HIV-PJP patients and 175 non-HIV-PJP patients were included.
Results:
Cough, dyspnea, typical computed tomography findings of PJP, and cytomegalovirus (CMV) pneumonitis co-infection were more common in the HIV-PJP group. The durations from symptom onset to PJ polymerase chain reaction (PCR) testing and to the start of treatment were longer in the HIV-PJP group; however, the time from the PJ PCR test to antibiotic administration was shorter in the HIV-PJP group. The 28-day survival rates were 68.6% and 88.6% in the non-HIV-PJP and HIV-PJP groups, respectively (p=0.011). The survival rate of patients with CMV pneumonitis co-infection in the non-HIV-PJP group was significantly lower.
Conclusion:
The clinical characteristics of patients with HIV-PJP and non-HIV-PJP were statistically different. The initial clinical features appeared to be worse in the HIV-PJP group; however, the 28-day mortality rate was higher in the non-HIV-PJP group.
More Related Videos
07:21Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
Published on: June 23, 2019
07:10Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:29Pneumonia II: Pathophysiology
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...